Coming soon: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
The soon available AmoyDx® FGFR1-4 NGS Panel (RUO) is an NGS assay for the qualitative detection of mutations (SNVs, InDels) and fusions in the FGFR1-4 genes on DNA and RNA from FFPE material. The panel covers the complete coding sequence of the four genes. As recommended in various publications (e.g. Lamarca, A. et al., 2023), the detection of FGFR gene fusions is carried out at the RNA level; unknown fusion partners can also be identified. The library is prepared using the hybrid capture method (ddCAP technology) with an optimized DNA/cDNA co-library preparation workflow, which mostly takes place in a single reaction tube.
As with all AmoyDx® NGS panels, the sequence data is analyzed locally using the AmoyDx® NGS Data Analysis System (ANDAS).
For further information, please contact us at molpath@zytomed-systems.de
1. Lamarca, A. et al. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma ESMO Open, Volume 8, Issue 6, 102049, 2023
Further topics
Breast Cancer Awareness Month
Breast cancer is one of the most common cancers in women worldwide. In Germany, every 8th woman is diagnosed with breast cancer. Until now, therapies have been based on the presence/absence of (hormone) receptors or the Her2 receptor in metastatic/non-metastatic breast cancer.
New NGS-Assay for HRD determination
The AmoyDx® HRD Complete Panel is an advanced development of the AmoyDx® HRD Focus Panel, which is already established in many laboratories for determining homologous recombination deficiency (HRD).
